Clinical Study
Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn’s Disease
Table 1
Demographic and clinical data at baseline of the treatment groups.
| | EEN | IFX |
| | N | 13 | 13 | | Sex (M, %) | 9, 69.2% | 6, 46.2% | | Age, years (range) | 11.9 (5.4–15.3) | 11.7 (1.1–13.7) | | PCDAI (mean ± S.D.) | 26.0 ± 9.3 | 29.5 ± 11.7 | | Disease duration (months, range) | 12.6 (1.1–91.7) | 12 (1.0–100.1) | | Disease location (%) | | | | Ileal (L1) | 23.1 | 15.4 | | Colonic (L2) | 0 | 38.5 | | Ileocolonic (L3) | 46.2 | 38.5 | | L4a | 7.7 | 0 | | L4b | 38.5 | 23.1 | | L4a + L4b | 30.8 | 38.5 | | Disease behavior (%) | | | | B1 | 92.3 | 100.0 | | B2 | 7.7 | 0 | | Perianal diseases (%) | 0 | 30.8 | | ESR (mm/H) | 38.0 ± 26.3 | 40.5 ± 33.0 | | HB (g/L) | 113.8 ± 12.3 | 109.8 ± 11.9 | | Albumin (g/L) | 37.3 ± 4.8 | 33.5 ± 7.3 |
|
|
EEN: exclusive enteral nutrition; IFX: infliximab; PCDAI: pediatric Crohn’s disease activity index; ESR: erythrocyte sedimentation rate; HB: hemoglobin.
|
